Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “With EGFR Mutations”

746 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 746 results

Testing effectiveness (Phase 2)Ended earlyNCT01857271
What this trial is testing

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer

Who this might be right for
Stage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer
Albert Einstein College of Medicine 3
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Testing effectiveness (Phase 2)Study completedNCT03812809
What this trial is testing

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Who this might be right for
NSCLC
Beta Pharma Shanghai 226
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)UnknownNCT05548348
What this trial is testing

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Who this might be right for
Non-small Cell Lung CancerEGFR G719XEGFR L861Q+1 more
Chongqing University Cancer Hospital 30
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Not applicableEnded earlyNCT03127449
What this trial is testing

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Advanced NSCLC
Allist Pharmaceuticals, Inc. 116
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Large-scale testing (Phase 3)Looking for participantsNCT05852990
What this trial is testing

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Instituto Nacional de Cancerologia de Mexico 28
Testing effectiveness (Phase 2)Study completedNCT01620190
What this trial is testing

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Who this might be right for
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
University of Washington 26
Large-scale testing (Phase 3)UnknownNCT02448797
What this trial is testing

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 320
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Testing effectiveness (Phase 2)Looking for participantsNCT06156527
What this trial is testing

Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Who this might be right for
Lazertinib
National Cancer Center, Korea 120
Not applicableStudy completedNCT03790397
What this trial is testing

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 169
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Testing effectiveness (Phase 2)UnknownNCT04063462
What this trial is testing

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Who this might be right for
Non Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Early research (Phase 1)Ended earlyNCT03082300
What this trial is testing

ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc. 3
Load More Results